Karyopharm Therapeutics (KPTI) Phase 3 BOSTON Study Meets Primary Endpoint with Significant Increase in PFS in Patients with Multiple Myeloma
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Karyopharm Therapeutics (KPTI) Prices 6.25M Share Common Offering at $24/Sh
March 4, 2020 5:54 AM ESTKaryopharm Therapeutics Inc. (NASDAQ: KPTI) today announced the pricing of its previously announced registered underwritten public offering of 6,250,000 shares of its common stock at a price to the public of $24.00 per share. The gross proceeds to Karyopharm from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, are expected to be $150.0 million. The offering is... More
Karyopharm Therapeutics (KPTI) Announces Proposed $150M Public Offering of Common Stock
March 2, 2020 4:17 PM ESTKaryopharm Therapeutics Inc. (Nasdaq: KPTI), an oncology-focused pharmaceutical company, today announced the commencement of a registered underwritten public offering of $150 million in shares of its common stock. In addition, Karyopharm also intends to grant the underwriters a 30-day option to purchase up to... More
Karyopharm Therapeutics (KPTI) PT Raised to $35 at Baird
March 2, 2020 8:29 AM ESTBaird analyst Michael Ulz raised the price target on Karyopharm Therapeutics (NASDAQ: KPTI) to $35.00 (from $25.00) while maintaining an Outperform rating following better-than-expected BOSTON study data.
The analyst commented, "This morning, Karyopharm announced highly anticipated Phase 3 results from the BOSTON study of... More
